Kornimate/medical-research-clean huggingface dataset:
study evaluating heated lidocaine/tetracaine patch in patients with pain associated with myofascial trigger points

Conditions: Myofascial Pain Syndromes

Summary: the purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.

the purpose of this pilot study is to explore the usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points. the study will consist of a 2-week, open-label treatment period followed by a 2 week follow-up period conducted at a single study site. eligible patients must have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 identifiable myofascial trigger points. a number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population.

Eligibility criteria:
inclusion criteria: * be at least 18 years of age * have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 myofascial trigger points * have trigger points confined to the upper back, shoulder, and neck exclusion criteria: * have used any topically applied pain medication on the target treatment area within 3 days preceding the screening/baseline visit * have used any topically applied pain medication on the target treatment area within 3 days preceding the screening/baseline visit * have used any injected pain medication with 28 days preceding the screening/baseline visit * are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.) other protocol-defined inclusion/exclusion criteria may apply.
stereotactic precision and conventional radiotherapy evaluation

Conditions: Non-small Cell Lung Cancer

Summary: a randomized phase ii study for medically inoperable stage i non-small cell lung cancer where stereotactic body radiotherapy in three fractions to 66 gy is compared with conventionally fractionated radiotherapy to 70 gy in 35 fractions.

this is a multicenter scandinavian randomized phase ii study of stereotactic hypofractionated radiotherapy with body frame versus conventionally fractionated radiotherapy for stage i medically inoperable non-small cell lung cancer patients. there is a 1:1 randomization between arm a: stereotactic radiotherapy to a dose of 66 gy with 22 gy per fraction at the isocenter (45 gy covers the ptv) in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour, and arm b: conventionally fractionated radiotherapy to a dose of 70 gy with 2 gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.

Eligibility criteria:
inclusion criteria: * non-small cell lung cancer stage i: t1-2 n0 m0. * medically inoperable patients or patients refusing surgery. * morphologically verified. if that is impossible there must be increased tumour size in repeated ct scans and positive pet. * patients should have a life expectancy of \> 6 months. * who performance status 0-2. * signed written informed consent obtained. * patient should be feasible for both study arms. exclusion criteria: * patients with central tumour growth adjacent to trachea, main bronchus or esophagus. * maximal tumour diameter \> 6 cm. * patients with prior malignancy within the last five years (except basal cell carcinoma of the skin or in situ carcinoma of the cervix). * any prior antitumoral treatment of the present lung cancer. * previous irradiation that included part of the lung. * pregnant women.

Keywords: non-small call lung cancer medically inoperable stage one radiotherapy sbrt hypofractionation conventional fractionation
study of lipid profile of patients with chronic coronary syndromes at sohag university hospital

Conditions: Ischemic Heart Disease; Dyslipidemias

Summary: chronic coronary syndrome (ccs) is a newly described classification devised by the european society of cardiology (esc) 2019 to replace the term "stable coronary artery disease (cad). the main reason for effecting the change is the term is thought to better describe the disease process and encompass a wider spectrum of clinical, pharmacological, and pathophysiological entities. using this new term, the disease atherosclerosis manifests as cad is categorized into acute coronary syndrome (acs) and ccs. the main focus of introducing the concept of ccs is on the fact that cad is a continuous phenomenon involving intravascular plaque aggregation and progression which has different evolutionary phases. dyslipidemia is recognized as a prominent risk factor for cardiovascular (cv) disease. it is characterized by an elevation of serum total cholesterol (tc), low-density lipoprotein cholesterol (ldl-c), or triglycerides (tg) and reduced serum high-density lipoprotein cholesterol (hdl-c) concentration . genetically determined and metabolically induced disturbances in lipid metabolism, as manifested in several types of dyslipidemia, have been shown to be causally related to the development of coronary artery disease (cad). a diversity of clinical and angiographic studies has been made to evaluate the linkage between plasma lipid-control therapy in the development of recurrent cardiovascular events. independent predictors of recurrent cvd events or death include age, smoking, hypertension (htn), dyslipidemia, diabetes mellitus, chronic kidney disease, and the underutilization of medications recommended by current treatment guidelines.


Eligibility criteria:
inclusion criteria: * all patients have chronic coronary disease at sohag university hospital who recieve drugs of anti hyperlipidemia . exclusion criteria: * patients with first attack of acute coronary syndrome . * young patients \<18 years . * old patients \>65 years.
exablate blood-brain barrier (bbb) disruption for the treatment of alzheimer's disease

Conditions: Alzheimer Disease

Summary: the purpose of this study is to evaluate the safety and efficacy of the exablate model 4000 type 2.0 system as a tool to disrupt the blood-brain barrier (bbb) in patients with probable alzheimer's disease (ad).

this is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of bbb disruption using the exablate model 4000 type 2.0 (220 khz) system. patients with diagnosis of probable alzheimer's disease may qualify for a clinical trial to have three serial exablate bbb disruption procedures in specific areas in the brain. this study will be conducted at up to 8 sites in the united states and will enroll up to 30 patients.

Eligibility criteria:
inclusion criteria: 1. male or female between 50-85 years of age 2. probable alzheimer's disease (ad) 3. if taking concurrent alzheimer's medication, has been on the medication for at least 2 months with a stable dose for at least 3 months 4. able to communicate sensations during the exablate mrgfus procedure 5. ambulatory exclusion criteria: 1. mri findings 2. presence of unknown or mr unsafe devices anywhere in the body 3. significant cardiac disease or unstable hemodynamic status 4. relative contraindications to ultrasound contrast agent or pet amyloid tracer 5. history of a bleeding disorder 6. history of liver disease 7. known cerebral or systemic vasculopathy 8. significant depression and at potential risk of suicide 9. any contraindications to mri scanning 10. any contraindication to lumbar puncture for collection of cerebral spinal fluid 11. untreated, uncontrolled sleep apnea 12. history of seizure disorder or epilepsy 13. severely impaired renal function 14. currently in a clinical trial involving an investigational product or non-approved use of a drug or device or in any other type of medical research 15. chronic pulmonary disorders 16. positive human immunodeficiency virus (hiv) 17. known apolipoprotein e allele (apoe4) homozygosity

Keywords: alzheimer disease alzheimer syndrome magnetic resonance guided focal ultrasound (mrgfus) blood-brain barrier exablate
comparisons of human fibrin glue (tisseel) versus suture and robotic versus traditional laparoscopy for ovarian cystectomy

Conditions: Women With Ovarian Cyst

Summary: objective: to compare the effects of suture versus human fibrin glue during robotic or laparoscopic ovarian cystectomy

methods: the medical records of all consecutive women who received robotic or laparoscopic ovarian cystectomy between january 2016 and may 2022 were reviewed. perioperative outcome and ovarian size were compared. expected results: we can get the effects of suture versus human fibrin glue during robotic or laparoscopic ovarian cystectomy. the above information should be important for consultation.

Eligibility criteria:
inclusion criteria: * \>20 years old women * women who received robotic or laparoscopic ovarian cystectomy between january 2016 and may 2022 were reviewed. exclusion criteria: * patients who underwent myomectomy at the same time.
urinary artificial sphincter in children

Conditions: Neurogenic Bladder Disorder; Bladder Dysfunction; Spina Bifida; Urinary Incontinence Due to Urethral Sphincter Incompetence; Child, Only

Summary: retrospective monocentric study of the outcomes of patients with neurogenic bladder who had a urinary artificial sphincter before the age of 18 years old. hypothesis: what was the impact of the urinary artificial sphincter on the global management of the patient?

the management of patients with neurogenic bladder is complex. several patients have been operated multiple times. surgical procedures such as mitrofanoff's, bladder neck surgery, bladder augmentation, and urinary artificial sphincter are common. the investigators wanted to analyze the participants' data, which led to the indication of a urinary artificial sphincter and its outcomes.

Eligibility criteria:
inclusion criteria: * patients who were younger than 18 years old when they had an urinary artificial sphincter exclusion criteria: * patients who were 18 years old or older when they had an urinary artificial sphincter

Keywords: urinary artificial sphincter neurogenic bladder child outcomes retrospective study
follow-up of the persistence of the complete molecular remission after stopping imatinib chronic myeloid leukemia

Conditions: Chronic Myeloid Leukemia

Summary: it's an observational study based on 98 patients included in the stim trial to extend the monitoring of patients and to have molecular and clinical data, with long follow up. are there late relapses? what has become patients who relapsed during stim trial and restarted tki (inhibitor tyrosine kinase) treatment?

chronic myeloid leukemia (cml) is an hematopoietic stem cell disorder in which a t (9;22) (q34;q11) reciprocal chromosomal translocation gives rise to philadelphia chromosome (ph) and generates the bcr-abl1 fusion gene encoding a constitutively activated protein tyrosine kinases (ptk). tyrosine kinase inibitors (tkis) such as imatinib, by blocking bcr-abl1 kinase activity, selectively eradicate cml cells and induce durable responses and prolong survival. cml patients treated with tki are monitored by bcr-abl1 rt-qpcr (reverse transcription real-time quantitative polymerase chain reaction) performed from peripheral blood samples. a first multicenter study entitled stim trial demonstrated that imatinib could be safely discontinued in patients with complete molecular remission (cmr) for at least 2 years (undetectable bcr-abl1 transcript by rt-qpcr). around 40% of these patients remain in a prolonged treatment-free remission (tfr) after treatment cessation. all molecular relapsing patients were sensitive when imatinib was re-challenged. the purpose of this stim-fu study is to follow all the patients included in the stim trial in order to evaluate their molecular status, vital status and ongoing treatment in patient with a first molecular relapse. this long term follow up will allow us to predict if a constant long term control of the disease is possible and to better define the clinical and biological cml-related factors predictive for a molecular relapse after tki discontinuation.

Eligibility criteria:
inclusion criteria: * the patients should have been included in the stim1 study chubx 2006/06 (nct00478985) exclusion criteria: * the patients not included or discharged prematurely from the stim1 study can not participate to the study
effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease. ratio-study. (by217/m2-112)

Conditions: Chronic Obstructive Pulmonary Disease; COPD

Summary: the purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (copd).


Eligibility criteria:
main inclusion criteria: * fev1/fvc ratio (post-bronchodilator) ≤70% * fev1 (post-bronchodilator) ≤50% of predicted * current smoker or ex-smoker * clinically stable copd indicated by no exacerbation and no change in copd treatment of within 4 weeks prior to baseline * availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit b0 or a willingness to have a chest x-ray performed before baseline main exclusion criteria: * copd exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline * lower respiratory tract infection not resolved 4 weeks prior to baseline * diagnosis of asthma and/or other relevant lung disease * known alpha-1-antitrypsin deficiency * need for long-term oxygen therapy defined as ≥16 hours/day

Keywords: roflumilast
histopathological comparison between superficial pressure ulcers and incontinence-associated dermatitis

Conditions: Pressure Ulcer; Incontinence-associated Dermatitis; Irritant Contact Dermatitis; Diaper Rash

Summary: this study aims to identify differences and similarities between superficial pressure ulcers (category ii and iii) and incontinence-associated dermatitis (category iia) at tissue level. skin biopsies will be obtained from 30 patients with pressure ulcers (n = 10), incontinence-associated dermatitis (n = 10), and combined lesions (n = 10). the results from the histopathologic examination will be compared with the clinical diagnosis by wound care experts, which will be based on photographs and relevant patients' characteristics.

despite current preventive strategies, prevalence of pressure ulcers and incontinence-associated dermatitis (iad) is still estimated at 5.9-6.9% in hospitalised patients, and 5.0-5.9 in home care patients. both skin conditions may occur in the same body region but are considered as separate entities, based on differences in etiology. at tissue level, it is assumed that pressure ulcers are characterised by ischemia and tissue deformation. in contrast, iad is assumed to be characterised by an irritative pattern. these assumptions are reflected in current preventive strategies. however, a small scale study, performed by houwing et al. (2007), described the additional presence of an ischemic pattern in patients with iad. more insights into the histopathologic pattern of pressure ulcers and iad is needed to optimise current preventive strategies. tha aim of this study is to compare superficial pressure ulcers (category ii and iii) and iad (category iia) at tissue level. a prospective interventional study will be performed during which skin biopsies (punch biopsies) will be collected from 30 incontinent patients. in each patient patient, two punch skin biopsies will be performed, one at the border of the skin lesion and one at the adjacent healthy skin. sections from the biopsies will be stained with hematoxiline and eosine and examined by two independently working, blinded skin pathologists. in addition, photographs from the skin lesions will be analysed by 10 national and international wound care experts to promote correct diagnosis. finally, findings from the histopathologic examination will be compared with the clinical diagnoses based on photographs.

Eligibility criteria:
inclusion criteria: * incontinent for urine, stool, or both * superficial pressure ulcer (category ii or iii) and/or incontinence-associated dermatitis (category iia) * expected length of stay of 7 days following punch skin biopsy exclusion criteria: * skin infection at biopsy site * medical contraindication to obtain a biopsy * end of life care * not able to provide informed consent

Keywords: pressure ulcer incontinence-associated dermatitis histopathology ischemia irritation prevention tissue skin
nocipoint therapy versus standard physical therapy using electrical stimulation in treating pain from tmj disorder

Conditions: Temporomandibular Joint Disorders

Summary: the purpose of this study is to measure the effect of nocipoint therapy on patients with temporomandibular joint disorders (tmd) and compare it with the effect of standard electrical stimulation therapy.

the prevalence of temporomandibular disorders (tmd) is about 20% to 60% of dental patients. most patients suffer from myofascial pain (mfp) subtype of tmd. analgesics, local muscle injection or oral appliance are often used to treat tmd-related mfp. patients are also referred to physical therapists frequently. many physical therapy (pt) modalities and techniques are applied to these patients, including non-invasive transcutaneous electrical nerve stimulation (tens) using tens devices. however, the exact application of tens devices, including the location of the stimulation, duration and intensity of stimulation, is largely decided by physical therapists. nocipoint therapy, a unique combination of precise location, duration and intensity of tens has been found to substantially relieve general myofascial pain and recover the muscle function with lasting effect. in preliminary observations of clinical applications, nocipoint therapy has been found to rapidly and substantially relieve tmd-related mfp within 2-3 sessions of the treatment. this clinical study compares the effect of nocipoint therapy on tmd with that of standard physical therapy (pt). tens will be used in the control group both as a part of the standard of care (i.e., pt) and as placebo.

Eligibility criteria:
inclusion criteria: * 20-65 years old female or male * diagnosed as mfp subtype of tmd according to rdc/tmd * pain duration over 3 month * tender point in masseter * asymmetrical pain intensity * subsided symptoms of joint inflammation exclusion criteria: * traumatic tmd from external impact force * history of traumatic cervical injury * presence of systemic disease * fibromyalgia * co-interventions for cervical problems or tmd during study period * signs of psychosomatic illness * unwilling to be randomized

Keywords: temporomandibular joint disorders nocipoint physical therapy
a survey collecting data on adult height in patients with achondroplasia treated with somatropin

Conditions: Genetic Disorder; Achondroplasia

Summary: this study is conducted in japan. the aim of the study is to evaluate the efficacy of somatropin (norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the gh-1941 study (nct01516229).


Eligibility criteria:
inclusion criteria: * patients who were enrolled in the gh-1941 study (1997 to 2006) and expected to theoretically reach the adult height within the study period
contralateral r1 in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als) is a neurodegenerative disease affecting both upper and lower motor neurons. electroneuromyography is an important tool for the diagnosis. previous studies have shown that different components of the blink reflex, such as the latencies of homo- and contralateral r2 responses can be affected. studies have found that a contralateral r1 component can appear in neurological diseases with affection of the central nervous system especially upper motor neuron, such as htlv1 infection. thus, you aim to determine if a contralateral r1 component could be present in als.


Eligibility criteria:
inclusion criteria: for patients * aged 18 to 99 years old * referred for suspected motor neuromuscular disease * collection of non-opposition for healthy subjects: * aged 18 to 99 years old * absence of any neurological pathology * collection of non-opposition exclusion criteria: * previous damage linked to another cause of the cranial nerves * prior brainstem lesions * persons deprived of liberty by a judicial or administrative decision * patient under judicial protection, unable to express consent

Keywords: amyotrophic lateral sclerosis als electroneuromyography enmg
effect of peer mentoring and blood pressure self-monitoring on hypertension control.

Conditions: Hypertension

Summary: cardiovascular diseases are increasing throughout the developing world and are the cause of almost 16.7 million deaths each year, of which 80% occur in low and middle-income countries. as more than three fourth of the global burden of cardiometabolic diseases are related to risk factors connected with lifestyles or behaviors, such as smoking, unhealthy eating, low physical activity, and harmful consumption of alcohol. this burden could be dramatically reduced by changing individual behaviors. this study is focused on interventions that are aimed to improve the adherence to treatment in cardiovascular disease (hypertension), based on a behavioral economics approach. most of public policies targeted to tackle noncommunicable diseases utilize a rational economic model of behavior. behavioral economics, by using insights from cognitive psychology and other social sciences, has drawn a lot of attention for its potential to increase healthy behaviors. interventions informed by behavioral economics principles seek to rearrange the social or physical environment in such a way to 'nudge' people towards healthier choices and behaviors. this is an individual controlled randomized trial which will be conducted to assess whether the implementation of two strategies, blood pressure self-monitoring plus signing a "contract of commitment", and peer mentoring are effective to reduce blood pressure values over a period of 3 months, compared to usual care. this randomized trial will enroll 430 patients from 10 public primary care clinics in argentina.


Eligibility criteria:
inclusion criteria: * adults (21 years and older) who only have public health coverage, and have high blood pressure (sbp ≥140 mmhg and / or dbp ≥90 mmhg) exclusion criteria: * pregnant women, bed-bound, and patients who cannot give informed consent.

Keywords: peer mentoring self-monitoring behavioral economics hypertension